PTC THERAPEUTICS, INC. The STRIVE program provides grants to non-profit patient advocacy organizations serving the Duchenne community. This year, grants will fund projects focused on formal learning, psychological support, sexuality, and skills-based training for people with Duchenne.
'We are proud to support the 2022 grant recipients for their work in the Duchenne community through our STRIVE Awards program. They have shown the broad range of needs in the Duchenne community, including programs supporting adults living with Duchenne,' said
The categories for the 2022 STRIVE Awards are 'Innovative' for programs that help to address the unmet needs of the rare disease community, and 'Transition to Adulthood' for programs that support young people with Duchenne as they transition into independent adults. 'Transition to Adulthood' is a category introduced last year to celebrate the initiatives that support those living with Duchenne to lead independent, fulfilling, and rewarding lives. This year, PTC received 40 applications from organizations around the world.
About the STRIVE Awards Program
PTC launched the Strategies to Realize Innovation, Vision, and Empowerment (STRIVE) Awards program in 2015 to support initiatives that benefit the Duchenne community by increasing awareness, diagnosis, and education, and fostering the development of future patient advocates. Each year, an independent panel of external experts with knowledge in rare diseases, patient advocacy and funding initiatives, judge the entries for innovation, vision, and empowerment. Thirty-nine projects supporting the Duchenne community have received STRIVE grants since the program's inception.
About Duchenne Muscular Dystrophy
Primarily affecting males, Duchenne muscular dystrophy is a rare and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death in the mid-twenties due to heart and respiratory failure. It is a progressive muscle disorder caused by the lack of functional dystrophin protein. Dystrophin is critical to the structural stability of all muscles, including skeletal, diaphragm, and heart muscles. Patients with Duchenne can lose the ability to walk (loss of ambulation) as early as age ten, followed by loss of the use of their arms. Duchenne patients subsequently experience life-threatening lung complications, requiring the need for ventilation support, and heart complications in their late teens and twenties.
About
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders.
Contact:
Tel: +1 (908) 300-0691
Email: kokeefe@ptcbio.com
(C) 2022 Electronic News Publishing, source
